Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Clinical characteristics and outcomes of extranodal marginal zone lymphoma of pulmonary mucosa-associated lymphoid tissue: A single-center retrospective study

Yu Qiu, Chunxia Zhang, Min Wang et al. Nov 03, 2025 pp. 7132-7132 10.1182/blood-2025-7132

Abstract Introduction: Extranodal marginal zone lymphoma of pulmonary mucosa-associated lymphoid tissue (MALT) is a rare, indolent lymphopro...

Peripartum FXI replacement supports safe neuraxial anesthesia in FXI-deficient parturients

Tabea Sutter, Juan Pablo Ghiringhelli Morales, Ronald George et al. Nov 03, 2025 pp. 3079-3079 10.1182/blood-2025-3079

Abstract Introduction Factor XI deficiency is an autosomal recessive bleeding disorder that poses challenges in peripartum management due to...

Monitoring of CNS involvement in AML using ultrahigh-sensitivity next-generation sequencing of cell-free DNA

Henri C. Hupe, Sophie Pietzka, Clara P. Wienecke et al. Nov 03, 2025 pp. 3515-3515 10.1182/blood-2025-3515

Abstract Introduction: Evaluation and monitoring of central nervous system (CNS) involvement in AML patients with standard of care methods (c...

Topical cyclosporine vs tacrolimus for ocular GVHD prophylaxis after outpatient allogeneic hematopoietic stem cell transplantation: A Phase I–II trial

Michelle Morcos, Graciela Gonzáles-Cantú, David Gomez-Almaguer et al. Nov 03, 2025 pp. 2478-2478 10.1182/blood-2025-2478

Abstract Background Ocular graft-versus-host disease (oGVHD) is a common complication after allogeneic hematopoietic ste...

Garp/LRRC32 defines the erythroid-megakaryocyte fate decision and enables β-globin program activation

Maria Velegraki, Bradley Blaser, Payton Weltge et al. Nov 03, 2025 pp. 206-206 10.1182/blood-2025-206

Abstract Erythroid commitment from multipotent progenitors is a tightly regulated process, yet the molecular drivers during the earliest sta...

Human HSPCs CRISPR-engineered to endogenously express oncogenic NRAS generate a transplantable lethal myeloid malignancy targetable with novel RAS therapeutics

Shirley Liu, Cailin Collins, James Chavez et al. Nov 03, 2025 pp. 5004-5004 10.1182/blood-2025-5004

Abstract Introduction: NRAS mutations are frequently found in human leukemias, including 20-30% of acute myeloid leukemia (AML) patients and...

Machine learning-based novel surfaceome classification system for acute myeloid leukemia

Heye Yu, Wenbing Liu, Qianqian Huang et al. Nov 03, 2025 pp. 452-452 10.1182/blood-2025-452

Abstract Objectives: Immunophenotyping of acute myeloid leukemia (AML) currently relies heavily on a limited panel of validated surface mark...

Molecular mutations may influence cytokine expression and critical illness subphenotyping in septic patients with Acute Myeloid Leukemia

Lukas Ronner, Sarah Skuli, Kaitlyn Housel et al. Nov 03, 2025 pp. 3376-3376 10.1182/blood-2025-3376

Abstract Background: In acute myeloid leukemia (AML), mutations in IDH1/2, RAS-family, FLT3, and TP53 have all been associated with unique in...

All-trans retinoic acid for refractory cancer therapy-induced thrombocytopenia: A new option beyond TPO-ras?

Linya Wang, Haitao Gao, Qiang Fu et al. Nov 03, 2025 pp. 1265-1265 10.1182/blood-2025-1265

Abstract Background: Cancer therapy-induced thrombocytopenia (CTIT) is a common hematologic toxicity in patients with solid tumors. It often...

Identification and characterization of human erythroblastic islands (EBIs) at single cell resolution

Raymond Doty, Adam Munday, Hannah Cottnair et al. Nov 03, 2025 pp. 181-181 10.1182/blood-2025-181

Abstract Nearly all red cell production takes place within erythroblastic islands (EBIs), a structure comprised of a central macrophage (CM)...

Single-cell RNA sequencing reveals cellular heterogeneity and molecular features of extramedullary-involved multiple myeloma

Yajun Wang, quande Lin, jiangxue Hou et al. Nov 03, 2025 pp. 7472-7472 10.1182/blood-2025-7472

Abstract Objective: Extramedullary multiple myeloma (EMM) is a highly aggressive subtype of multiple myeloma (MM), characterized by the diss...

Sustained MRD negativity via multimodal NGS/NGF overcomes high-risk cytogenetics and predicts long-term survival in transplant-eligible multiple myeloma: A real-world cohort study

Yuhe Peng, Li Yao, Mingqing Zhu et al. Nov 03, 2025 pp. 5796-5796 10.1182/blood-2025-5796

Abstract Background: Dozens of clinical trials demonstrated that achievement of MRD negativity represents a paradigm shift in MM therapeutic...

Lentiviral hematopoietic stem and progenitor cell gene therapy with Etuvetidigene autotemcel for the treatment of Wiskott-Aldrich Syndrome

Francesca Ferrua, Sabina Cenciarelli, Stefania Giannelli et al. Nov 03, 2025 pp. 6092-6092 10.1182/blood-2025-6092

Abstract BACKGROUND Wiskott-Aldrich Syndrome (WAS) is a rare, X-linked, life-threatening inborn error of immunity and pl...

Bioflipi scores define distinct immune profiles in follicular lymphoma

Jordan Krull, Qin Ma, Emmanuel Contreras Guzman et al. Nov 03, 2025 pp. 5328-5328 10.1182/blood-2025-5328

Abstract Despite a characteristic indolent course, a substantial subset of follicular lymphoma (FL) patients has an early relapse with a poo...

Renal amyloidosis-related mortality trends and disparities: A retrospective nationwide analysis using the CDC wonder database

Aqsa Sorathia, Anusha Akhai, Bassel Aldroubi et al. Nov 03, 2025 pp. 3964-3964 10.1182/blood-2025-3964

Abstract Background Renal amyloidosis is a rare but life-threatening condition characterized by extracellular deposition...

Methimazole-triggered pancytopenia in a long-term methotrexate user: Dual-agent myelotoxicity

Ilias Jerrar, Shreeram Paudel, Reem Akel et al. Nov 03, 2025 pp. 6737-6737 10.1182/blood-2025-6737

Abstract Background: Methotrexate (MTX), a mainstay in the treatment of autoimmune disorders such as rheumatoid arthritis, is generally well...

Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma

Yinqiang Zhang, Lin Liu, Liman Su et al. Nov 03, 2025 pp. 7261-7261 10.1182/blood-2025-7261

Abstract Introduction: Chimeric antigen receptor (CAR) T-cells have improved outcomes of patients (pts) with relapsed/re...

Disseminated intravascular coagulation: An uncommon initial manifestation of AML presenting with embolic stroke

John Iwaniec, Ardit Feinaj, Devesh Amin et al. Nov 03, 2025 pp. 6919-6919 10.1182/blood-2025-6919

Abstract Introduction: Disseminated intravascular coagulation (DIC) is classically associated with acute promyelocytic leukemia (APL), but i...

Uncovering idiopathic hypereosinophilic syndrome: A diagnostic journey through eosinophilia .

Mai Abouzeid, Mohamed Ghonim, Ahmed Elkalashy et al. Nov 03, 2025 pp. 6560-6560 10.1182/blood-2025-6560

Abstract Eosinophilia is defined as an increase in the eosinophil count in the peripheral blood, specifically characterized by an absolute e...

Novel therapeutics for SF3B1 mutant cancers which exploit the missplicing of DCAF16

Michal Sekrecki, Agata Sekrecka, Rohan Lattupally et al. Nov 03, 2025 pp. 1474-1474 10.1182/blood-2025-1474

Abstract Oncogenic mutations of the core RNA splicing factor SF3B1 are common in myeloid cancers, chronic lymphocytic leukemia (CLL) and sel...

FLAG-mitoxantrone combined with low-dose venetoclax (7 Days): A highly efficient regimen and excellent bridge for allogeneic hematopoietic transplant for newly diagnosed and relapsed/refractory AML.

Ahmad Ibrahim, Kamal Al Zahran, Ahmad Khalil et al. Nov 03, 2025 pp. 5177-5177 10.1182/blood-2025-5177

Abstract Background FLAG (G-CSF, Fludarabine, Cytarabine) combined with either Idarubicin (Ida) or Mitoxantrone (Mitox) were reported to be...

DDX41-R525H mutation promotes dysplastic hematopoiesis via aberrant splicing of key regulators of HSC biology

Rasika Venkataraman, Jahan Rahman, Takero Miyagawa et al. Nov 03, 2025 pp. 677-677 10.1182/blood-2025-677

Abstract Germline mutations in the RNA helicase DDX41 are the most common genetic predisposition to myelodysplastic syndromes (MDS) and acut...

Development and prospective validation of a prognostic model for diffuse alveolar hemorrhage after allogeneic hematopoietic stem cell transplantation

Qiu-Sha Huang, Zhuo-Yu An, Peng Zhao et al. Nov 03, 2025 pp. 4276-4276 10.1182/blood-2025-4276

Abstract Introduction Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication that can occur after allogeneic hematop...

Multi-omic analysis reveals metabolic fitness of the ARI0002h BCMA CAR T-cell infusion product as a key predictor of clinical outcomes in multiple myeloma

Joan Mañé Pujol, Anna de Daniel, David Moreno et al. Nov 03, 2025 pp. 2294-2294 10.1182/blood-2025-2294

Abstract Background BCMA-directed CAR-T therapies have achieved high initial responses in relapsed/refractory (R/R) multiple myeloma (MM). A...

Clinical value of advanced genomic testing in adult Philadelphia-negative B-ALL: Results from the CZ national leukemia study group (CELL)

Zuzana Vrzalova, Vaclava Polivkova, Jitka Krizkova et al. Nov 03, 2025 pp. 1587-1587 10.1182/blood-2025-1587

Abstract IntroductionB-cell precursor acute lymphoblastic leukemia (B-ALL) in adults is a biologically and clinically heterogeneous disease....

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page